Search Result

Results for "

IFNα

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Payload (1) Apoptosis (5) Autophagy (3) Biochemical Assay Reagents (1) CD1 (1) Cyclic GMP-AMP Synthase (1) DNA/RNA Synthesis (2) Drug Derivative (1) Drug Isomer (1) Drug Metabolite (1) Endogenous Metabolite (1) ERK (1) Fc Receptor (FcR) (1) FXR (1) HBV (4) HCV (3) HIV (1) IFNAR (30) Indoleamine 2,3-Dioxygenase (IDO) (1) Interleukin Related (6) IRAK (3) Isotope-Labeled Compounds (1) JAK (10) JNK (1) mRNA (1) PD-1/PD-L1 (2) Phosphodiesterase (PDE) (2) Progesterone Receptor (2) PROTACs (1) Reference Standards (3) SARS-CoV (3) Sodium Channel (1) STAT (5) STING (2) TNF Receptor (5) Toll-like Receptor (TLR) (32)
By Research Areas:	Cancer (19) Infection (14) Inflammation/Immunology (60) Metabolic Disease (3)
Oligonucleotides:	CpG ODNs (24) mRNA (1) Uracil (1) Phosphoramidites (1) Interleukin & Receptors (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13740

Resiquimod Maximum Cited Publications 110 Publications Verification R848; S28463	Toll-like Receptor (TLR) HCV	Inflammation/Immunology Cancer
Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α.

HY-12836A

IFN alpha-IFNAR-IN-1 hydrochloride 20+ Cited Publications	IFNAR	Inflammation/Immunology
IFN alpha-IFNAR-IN-1 hydrochloride is a nonpeptidic, low-molecular-weight inhibitor of the interaction between IFN-α and IFNAR. IFN alpha-IFNAR-IN-1 hydrochloride inhibits modified Vaccinia virus ankara (MVA)-induced IFN-α responses in murine bone-marrow-derived, Flt3- L-differentiated pDC cultures (BM-pDCs) (IC₅₀=2-8 μM) .

HY-150738

ODN 2088 3 Publications Verification	Toll-like Receptor (TLR)	Inflammation/Immunology
ODN 2088 is a potent TLR3, TLR7 and TLR9 inhibitor. ODN 2088 shows no cytotoxic. ODN 2088 inhibits the release of IFN-α and IL-6 .

HY-109197

Vonafexor 2 Publications Verification EYP001	FXR HBV	Infection
Vonafexor (EYP001) is an orally active, non-steroidal and selective FXR agonist. Vonafexor shows significant HBsAg reduction when combined with Peg-IFNα. Vonafexor can be used for anti-HBV research .

HY-137978A

Ezurpimtrostat hydrochloride 3 Publications Verification GNS561 hydrochloride	SARS-CoV IFNAR Autophagy Apoptosis	Metabolic Disease Inflammation/Immunology Cancer
Ezurpimtrostat hydrochloride (GNS561 hydrochloride) is an orally active PPT1 inhibitor, autophagy inhibitor, immunomodulator, anti-inflammatory agent, and anticancer agent. Ezurpimtrostat hydrochloride inhibits PPT1, dysregulates lysosomal function, redistributes mTOR, and induces apoptosis. Ezurpimtrostat hydrochloride reduces *IFN‑α, CRP, immune complex deposition, and SARS‑CoV‑2* viral load. Ezurpimtrostat hydrochloride can be used for the study of systemic lupus erythematosus, SARS‑CoV‑2, hepatocellular carcinoma, fibrosis, and related disorders .

HY-P99300

Ligelizumab 1 Publications Verification QGE 031; Anti-IGHE Recombinant Antibody	Fc Receptor (FcR)	Inflammation/Immunology
Ligelizumab (QGE 031) is a humanized high-affinity anti-immunoglobulin IgE monoclonal antibody. Ligelizumab selectively inhibits the binding of IgE to the high-affinity receptor FcεRI, while the inhibitory effect on the low-affinity receptor CD23 is weak. Ligelizumab can inhibit the activation of effector cells such as mast cells and Basophil, while reducing the production of IgE by B cells, and restoring the *IFN-α* production and regulatory T cell (Treg) induction function of plasmacytoid dendritic cells (pDC). Ligelizumab can be used in the study of allergic diseases (such as chronic spontaneous urticaria, allergic asthma) .

HY-P99219

Sifalimumab MEDI-545; MDX 1103	IFNAR	Inflammation/Immunology
Sifalimumab (MEDI-545) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research .

HY-111358

TLR7 agonist 1	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7 agonist 1 is a selective TLR7 agonist with an LEC value of 90 nM. TLR7 agonist 1 activates downstream immune regulation and shows no activity against TLR8. TLR7 agonist 1 induces endogenous IFN-α production in mice .

HY-150217

CpG ODN 10101 2 Publications Verification ODN 10101	Toll-like Receptor (TLR)	Infection Inflammation/Immunology
CpG ODN 10101 (ODN 10101; CPG 10101) is a selective agonist targeting TLR9, a synthetic oligodeoxynucleotide modified with phosphate thioester. CpG ODN 10101 activates B cells and plasmacytoid dendritic cells (pDCs), inducing the production of cytokines and chemokines such as interferon-IFN-α, interferon-inducible protein IP-10, and 2'5'-oligoadenylate synthase (2'5'-OAS), regulating innate immunity and promoting Th1 adaptive immune responses. CpG ODN 10101 also possesses antiviral properties and enhances vaccine immunogenicity, making it suitable as an immunomodulator and vaccine adjuvant for vaccine development in chronic hepatitis C and infectious diseases such as melioidosis, pertussis, and respiratory syncytial virus (RSV) .

HY-W011890

Cridanimod 1 Publications Verification	Progesterone Receptor IFNAR	Inflammation/Immunology Cancer
Cridanimod is a potent progesterone receptor (PR) activator mediated through induction of *IFNα* and IFNβ expression. Cridanimod is a small-molecule immunomodulator and interferon inducer .

HY-100544

FLLL32 5+ Cited Publications	STAT JAK Apoptosis	Cancer
FLLL32, a synthetic analog of curcumina, is a JAK2/STAT3 dual inhibitor with anti-tumor activity. FLLL32 can inhibit the induction of STAT3 phosphorylation by IFNα and IL-6 in breast cancer cells .

HY-P99348

Ropeginterferon alfa-2b Ropeginterferon alfa-2b-njft; PEG-proline-interferon alpha-2b	Apoptosis	Cancer
Ropeginterferon alfa-2b (Ropeginterferon alfa-2b-njft) is a monopegylated IFN-α that can be used for the research of myeloproliferative neoplasms .

HY-101762

TyK2-IN-2	JAK Phosphodiesterase (PDE)	Inflammation/Immunology
TyK2-IN-2 (Compoud 18) is a potent and selective TYK2 inhibitor with IC₅₀s of 7 nM, 0.1 μM and 0.05 μM for TYK2 JH2, IL-23 and *IFNα, respectively. TyK2-IN-2 also inhibits phosphodiesterase 4 (PDE4)* with an IC₅₀ of 62 nM. TyK2-IN-2 can be used for the research of inflammatory and autoimmune diseases .

HY-137978

Ezurpimtrostat 3 Publications Verification GNS561	SARS-CoV IFNAR Autophagy Apoptosis	Infection Metabolic Disease Inflammation/Immunology Cancer
Ezurpimtrostat (GNS561) is an orally active PPT1 inhibitor, autophagy inhibitor, immunomodulator, anti-inflammatory agent, and anticancer agent. Ezurpimtrostat inhibits PPT1, dysregulates lysosomal function, redistributes mTOR, and induces apoptosis. Ezurpimtrostat reduces *IFN‑α, CRP, immune complex deposition, and SARS‑CoV‑2* viral load. Ezurpimtrostat can be used for the study of systemic lupus erythematosus, SARS‑CoV‑2, hepatocellular carcinoma, fibrosis, and related disorders .

HY-126242S

Tyk2-IN-7	JAK IFNAR Interleukin Related	Inflammation/Immunology
Tyk2-IN-7 is an orally active TYK2 JH2 inhibitor, binds to TYK2 JH2 domain with IC₅₀ and K_i.app of 0.00053 μM and 0.00007 μM, respectively. Tyk2-IN-7 provides a highly selective alternative to conventional TYK2 orthosteric inhibitors, inhibits TYK2/JAK1/JAK2 kinase domain. Tyk2-IN-7 can inhibit the IL-23 and *IFN-α* signaling pathways. Tyk2-IN-7 is commonly used in the study of inflammatory conditions such as colitis .

HY-128854

Dimethyl biphenyl-4,4'-dicarboxylate 1 Publications Verification	Biochemical Assay Reagents JAK STAT IFNAR DNA/RNA Synthesis HBV	Infection Metabolic Disease
Dimethyl biphenyl-4,4'-dicarboxylate (Biphenyl dimethyl dicarboxylate) is a hepatoprotective agent. Dimethyl biphenyl-4,4'-dicarboxylate stimulates the Jak/Stat signaling pathway and induces the expression of *IFN-α*-stimulated genes, particularly 6-16 and ISG12. Dimethyl biphenyl-4,4'-dicarboxylate inhibits the replication of pregenomic RNA and HBeAg. Polymer micelles loaded with Dimethyl biphenyl-4,4'-dicarboxylate can serve as carriers for the compound. Dimethyl biphenyl-4,4'-dicarboxylate can be used as an auxiliary improving agent for chronic hepatitis. Dimethyl biphenyl-4,4'-dicarboxylate is applicable to research related to chronic hepatitis B .\n

HY-111745

Tyk2-IN-5	JAK	Inflammation/Immunology
Tyk2-IN-5 (compound 6) is a potent, selective and orally active tyrosine kinase 2 (Tyk2) inhibitor that acts on the JH2 structural domain. Tyk2-IN-5 shows a K_i value of 0.086 nM for Tyk2 JH2 and an IC₅₀ value of 25 nM for IFNα. Tyk2-IN-5 efficiently inhibits the production of IFNγ in a pharmacodynamic rat model and is fully efficacious in a rat model of arthritis .

HY-150738C

ODN 2088 sodium 3 Publications Verification	Toll-like Receptor (TLR)	Inflammation/Immunology
ODN 2088 sodium is a potent TLR3, TLR7 and TLR9 inhibitor. ODN 2088 sodium shows no cytotoxic. ODN 2088 inhibits the release of IFN-α and IL-6 .

HY-148238

GNE-2256	IRAK	Inflammation/Immunology
GNE-2256 (molecule 19), a chemical probe, is an orally active IRAK4 (Interleukin 1 receptor associated kinase 4) inhibitor (IRAK4 K_i=1.4 nM; IL-6 IC₅₀=190 nM) .

HY-155863

AJ2-71	Sodium Channel	Inflammation/Immunology
AJ2-71 is a SLCl5A4 inhibitor. AJ2-71 inhibits IFN-α production. AJ2-71 blocks SLC15A4-mediated MDP transport. AJ2-71 can be used for research of inflammation .

HY-170331

IFNα-IN-1	IFNAR	Inflammation/Immunology
IFNα-IN-1 (AJ2-18) is a *IFNα* inhibitor that inhibits IFN-α production. IFNα-IN-1 can be used for research of inflammation .

HY-118250

GSK2245035 2 Publications Verification	Toll-like Receptor (TLR) IFNAR TNF Receptor	Inflammation/Immunology
GSK2245035 is a highly potent and selective intranasal Toll-Like receptor 7 (TLR7) agonist with preferential Type-1 interferon (IFN)-stimulating properties. GSK2245035 has pEC₅₀s of 9.3 and 6.5 for IFNα and TFNα. GSK2245035 effectively suppresses allergen-induced Th2 cytokine production in human peripheral blood cell cultures. GSK2245035 is used for asthma .

HY-148511

Vidutolimod CMP-001	Toll-like Receptor (TLR) IFNAR PD-1/PD-L1 Indoleamine 2,3-Dioxygenase (IDO)	Cancer
Vidutolimod (CMP-001) is a virus-like particle containing a TLR9 activator . Vidutolimod induces human peripheral blood mononuclear cells to secrete *IFNα, and upregulates the gene expression of CXCL10, PDL1, IDO* and CD80. Vidutolimod activates TLR9, which in turn triggers plasmacytoid dendritic cell activation, production of IFNγ and TNFα, induction of CXCL10, and recruitment of antitumor T cells. Vidutolimod causes influenza-like symptoms, hypotension and tumor regression, and its activity depends on the presence of anti-Qβ antibodies. Vidutolimod modulates monocyte function, promotes CD4 T cell proliferation, and activates multiple immune cell types in an environment with anti-Qβ antibodies. Vidutolimod prolongs the survival of tumor-bearing mice. Vidutolimod is used in research related to advanced melanoma, head and neck squamous cell carcinoma, and advanced non-small cell lung cancer .

HY-12836

IFN alpha-IFNAR-IN-1 20+ Cited Publications	IFNAR	Inflammation/Immunology
IFN alpha-IFNAR-IN-1 is a nonpeptidic, low-molecular-weight inhibitor of the interaction between IFN-α and IFNAR. IFN alpha-IFNAR-IN-1 inhibits modified Vaccinia virus ankara (MVA)-induced IFN-α responses in murine bone-marrow-derived, Flt3- L-differentiated pDC cultures (BM-pDCs) (IC₅₀=2-8 μM) .

HY-148511A

Vidutolimod sodium CMP-001 sodium	Toll-like Receptor (TLR)	Cancer
Vidutolimod sodium is a CpG-A oligodeoxynucleotide. Vidutolimod sodium is a Toll-like receptor 9 (TLR9) agonist, which activates plasmacytoid dendritic cells (pDCs) and triggers interferon alpha (IFNα) release, leading to a cascade of anti-tumor immune effects.

HY-13740S

Resiquimod-d5 1 Publications Verification R848-d₅; S28463-d₅	Isotope-Labeled Compounds Toll-like Receptor (TLR) HCV	Infection Inflammation/Immunology
Resiquimod-d₅ is deuterium labeled Resiquimod. Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α .

HY-150742A

ODN 2336 sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
ODN 2336 sodium is a A-Class CpG ODN (oligodeoxynucleotides), is a potent TLR9 agonist. ODN 2336 sodium induces the production of IFN-α. ODN 2336 sodium up-regulates the expression of IP-10 mRNA and IL-18 mRNA. ODN 2336 sodium can be used as adjuvant of vaccines .

HY-153840A

ODN INH 18 sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
ODN INH-18 sodium is a linear 24-mer class B INH-ODN in which the 5' INH-ODN 4084-F sequence was followed by a random stretch of 12 nucleotides lacking the ability to form significant secondary structures. ODN INH-18 sodium showes inhibitory potency for TLR9 ligand-induced IFN-α production.

HY-160231

ssRNA42 sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
ssRNA42 (sodium) is a 20-mer phosphothioate protected single-stranded RNA oligonucleotide. ssRNA42 (sodium) derives from ssRNA40 by replacement of all G nucleotides with adenosine. ssRNA42 activated human PBMCs to secrete IFN-α, TNF-a, IL- 12p40, and IL-6, but ssRNA42 failed to stimulated murine pDCs and PBMCs.

HY-150745A

ODN 24987 sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
ODN 24987 sodium is a Guanine-modified inhibitory oligonucleotides (ODN), targeting TLR9. ODN 24987 can inhibit IL-6 and IFN-α release. ODN 24987 sodium can be used for research immune disorders. ODN 24987 sequence: 5’-C-C-T-G-G-C-c7G-G-G-G-3’ .

HY-171692

G3-YSD	Cyclic GMP-AMP Synthase IFNAR STING	Infection
G3-YSD is a cGAS agonist. G3-YSD directly interacts with cGAS to enhance its enzymatic activity, promote the conversion of ATP and GTP into cGAMP, and trigger STING-dependent *IFN-α/β* secretion. G3-YSD acts as a viral mimic to replace actual viral DNA . G3-YSD is applicable to research related to long COVID and type 1 human immunodeficiency virus infection .

HY-148980A

Polyinosinic acid sodium 1 Publications Verification	Toll-like Receptor (TLR)	Inflammation/Immunology
Polyinosinic acid sodium is the sodium form of Polyinosinic acid (HY-148980). Polyinosinic acid is a single stranded homonucleic acid, which is a Toll-like Receptor 3 (TLR3) ligand. Polyinosinic acid enhances cellular immune response through TLR3 and TRIF. Polyinosinic acid has potential applications in immune regulation .

HY-173357

TYD-68	PROTACs JAK STAT	Inflammation/Immunology
TYD-68 is a highly efficient and selective CRBN-recruited TYK2 PROTAC degrader with a DC₅₀ value of 0.42 nM. TYD-68 significantly inhibits IL-12 and *IFN-α*-induced STAT4 and STAT1 phosphorylation, thereby blocking TYK2-dependent signaling pathways. TYD-68 can be used in the study of psoriasis. (Pink: Target protein ligand (HY-173359); Black: Linker (HY-W007732B); Blue: E3 ligase ligand (HY-14658); E3 ligase ligand + Linker (HY-173358)) .

HY-W570886

2'-O-MOE-U	DNA/RNA Synthesis	Cancer
2'-O-MOE-U is a nucleic acid modification group (Phosphoramidite) with 3'-exonuclease inhibitory activity. 2'-O-MOE-U also exhibits gene silencing activity and double-stranded oligonucleotide stability. By forming steric interactions with 3'-exonuclease residues, 2'-O-MOE-U anchors the 3'-end of the siRNA guide strand in the hAgo2 PAZ domain, thereby regulating double-stranded thermal stability and enhancing base-pairing specificity. 2'-O-MOE-U does not induce IFNα production, can be incorporated at multiple sites of siRNA to enhance RNAi activity, and produces a synergistic effect with 2'-F modification. 2'-O-MOE-U has been widely used in studies related to breast cancer and other diseases .

HY-156466

QL-1200186	STAT Interleukin Related IFNAR	Inflammation/Immunology
QL-1200186 is a selective, orally active, allosteric inhibitor targeting the tyrosine kinase TYK2 pseudokinase domain JH2 (IC₅₀=0.06 nM, TYK2 JH2), with 164-fold selectivity over TYK1 JH2 (IC₅₀=9.85 nM，TYK1 JH2). QL-1200186 first stabilizes the TYK2 JH2 conformation, inhibits the activity of the JH1 catalytic domain, and blocks the *IFNα, IL-12/IL-23-mediated JAK-STAT* signaling pathway. QL-1200186 can inhibit the production of Th1/Th17 cell-related cytokines (such as IFNγ, IL-23), reduce immune cell activation, and has no significant effect on JAK1/2/3 kinase activity. QL-1200186 can significantly improve skin inflammation in the Imiquimod (HY-B0180)-induced psoriasis mouse model and reduce the Psoriasis Area and Severity Index (PASI) score. QL-1200186 can be used in the study of autoimmune diseases such as psoriasis and systemic lupus erythematosus (SLE) .

HY-150739A

ODN 21158 sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
ODN 21158 sodium is a potent G-modified TLR3 and TLR9 inhibitor. ODN 21158 sodium inhibits IFN-α secretion in a dose dependent manner .

HY-150739

ODN 21158	Toll-like Receptor (TLR)	Inflammation/Immunology
ODN 21158 is a potent G-modified TLR3 and TLR9 inhibitor. ODN 21158 shows no cytotoxic. ODN 21158 inhibits IFN-α secretion in a dose dependent manner .

HY-150747A

ODN 6016 sodium	IFNAR	Inflammation/Immunology
ODN 6016 sodium is a CpG-A oligonucleotides. ODN 6016 sodium can induce *IFN-α* production, and can be used for researching immune disorders including immunodeficiency caused by HIV-1. ODN 6016 sequence: T-sp-C-G-A-C-G-T-C-G-T-G-G-sp-G-sp-G-sp-G .

HY-150747

ODN 6016	IFNAR	Inflammation/Immunology
ODN 6016 is a CpG-A oligonucleotides. ODN 6016 can induce *IFN-α* production, can be used for researching immune disorders including immunodeficiency caused by HIV-1. ODN 6016 sequence: T-sp-C-G-A-C-G-T-C-G-T-G-G-sp-G-sp-G-sp-G .

HY-176553

KBD4466	Toll-like Receptor (TLR) Interleukin Related IFNAR	Inflammation/Immunology
KBD4466 is an orally active potent TLR7 and TLR8 inhibitor with IC₅₀s of 0.9 nM and 2.8 nM, respectively. KBD4466 inhibits the expression of inflammatory cytokines IL-6 and IFN-α. KBD4466 improves disease progression and survival in the BXSB/MpJ mouse model of Systemic Lupus Erythematosus (SLE). KBD4466 can be used in the study of autoimmune diseases .

HY-150749A

ODN D-SL03 sodium	IFNAR	Cancer
ODN D-SL03 sodium is a C class CpG oligonucleotides, and can induce stimulate PBMCs to produce high level of *IFN-α*. ODN D-SL03 sodium can activate human B cells, NK cells and mononuclear cells and up-regulate expression of CD80, CD86 and HLA-DR on the surface of subsets in human PBMCs. ODN D-SL03 sodium also can inhibit the growth of the tumor. ODN D-SL03 sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3' .

HY-175983

JAK1/TYK2-IN-5	JAK	Cancer
JAK1/TYK2-IN-5 (compound A1) is a JAK1/TYK2 inhibitor with K_i values of 0.0044 nM, 0.02 nM, 6.9 μM, 0.79 μM, 0.21 μM and 0.55 μM for TYK2 JH2, JAK1 JH2, JAK1 JH1, JAK2 JH1, JAK3 JH1 and TYK2 JH1, respectiverly. JAK1/TYK2-IN-5 inhibts IFNα induced TYK2/JAK1-mediated STAT activation .

HY-150742

ODN 2336	Toll-like Receptor (TLR)	Inflammation/Immunology
ODN 2336 is a A-Class CpG ODN (oligodeoxynucleotides), is a potent TLR9 agonist. ODN 2336 induces the production of IFN-α. ODN 2336 up-regulates the expression of IP-10 mRNA and IL-18 mRNA. ODN 2336 can be used as adjuvant of vaccines .

HY-178012

GLPG4471	IRAK TNF Receptor	Inflammation/Immunology
GLPG4471 is a selective and orally active IRAK4 inhibitor with an IC₅₀ of 1.7 nM. GLPG4471 exhibits potent inhibition of cytokine (TNFα and *IFNα*) secretion in cellular and whole blood phenotypic assays. GLPG4471 displays significant activity in a mouse model of collagen-induced arthritis. GLPG4471 can be used for the study of arthritis .

HY-150744A

ODN 24888 sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
ODN 24888 sodium is an guanine-modified inhibitory oligonucleotides (INH-ODN), shows potent inhibition on TLR7/TLR9-mediated signaling. ODN 24888 sodium impairs IFN-α level and NF-κB activation, inhibits IL-6 release. ODN 24888 sodium involves in immune and inflammatory responses, can be used as a vaccine adjuvant .

HY-150745

ODN 24987	Toll-like Receptor (TLR)	Inflammation/Immunology
ODN 24987 is a Guanine-modified inhibitory oligonucleotides (ODN), targeting TLR9. ODN 24987 can inhibit IL-6 and IFN-α release. ODN 24987 can be used for research immune disorders. ODN 24987 sequence: 5’-C-C-T-G-G-C-c7G-G-G-G-3’ .

HY-N8107

Matairesinol monoglucoside 2 Publications Verification	STING IFNAR HBV	Infection
Matairesinol monoglucoside is a STING activator. Matairesinol monoglucoside modulates the STING-TBK1-IRF3 signaling axis, promotes STING transcriptional expression, increases TBK1 and IRF3 phosphorylation. Matairesinol monoglucoside induces IFN-α and IFN-β production, reduces HBV DNA, HBsAg, and HBeAg expression. Matairesinol monoglucoside can be used for the research of hepatitis b virus (hbv) infection .

HY-173070

TLR7 agonist 29	Toll-like Receptor (TLR) IFNAR PD-1/PD-L1 ADC Payload	Inflammation/Immunology Cancer
TLR7 agonist 29 (Compound 1) is the agonist for TLR7 with an EC₅₀ of 5.2 nM for human TLR7 (EC₅₀ for mouse TLR7 is 48.2 nM). TLR7 agonist 29 activates bone marrow-derived macrophages (BMDMs), stimulates myeloid cells in the tumor microenvironment, promotes the expression of PD-L1, CD86 and IFN-α. TLR7 agonist 29 can be used as payload for synthesis of ADC .

HY-P1758

IFN-α Receptor Recognition Peptide 1 IRRP1	IFNAR	Infection
IFN-α Receptor Recognition Peptide 1 is a peptide of IFN-α associated with receptor interactions .

HY-148980

Polyinosinic acid	Toll-like Receptor (TLR)	Inflammation/Immunology
Polyinosinic acid is a single stranded homonucleic acid, which is a Toll-like Receptor 3 (TLR3) ligand. Polyinosinic acid enhances cellular immune response through TLR3 and TRIF. Polyinosinic acid has potential applications in immune regulation .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99300

Ligelizumab 1 Publications Verification QGE 031; Anti-IGHE Recombinant Antibody	Fc Receptor (FcR)	Inflammation/Immunology
Ligelizumab (QGE 031) is a humanized high-affinity anti-immunoglobulin IgE monoclonal antibody. Ligelizumab selectively inhibits the binding of IgE to the high-affinity receptor FcεRI, while the inhibitory effect on the low-affinity receptor CD23 is weak. Ligelizumab can inhibit the activation of effector cells such as mast cells and Basophil, while reducing the production of IgE by B cells, and restoring the *IFN-α* production and regulatory T cell (Treg) induction function of plasmacytoid dendritic cells (pDC). Ligelizumab can be used in the study of allergic diseases (such as chronic spontaneous urticaria, allergic asthma) .

HY-P99219

Sifalimumab MEDI-545; MDX 1103	IFNAR	Inflammation/Immunology
Sifalimumab (MEDI-545) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research .

HY-P99348

Ropeginterferon alfa-2b Ropeginterferon alfa-2b-njft; PEG-proline-interferon alpha-2b	Apoptosis	Cancer
Ropeginterferon alfa-2b (Ropeginterferon alfa-2b-njft) is a monopegylated IFN-α that can be used for the research of myeloproliferative neoplasms .

HY-P99267

Rontalizumab RhuMab IFNalpha; Anti-Human IFN alpha Recombinant Antibody	Inhibitory Antibodies	Inflammation/Immunology
Rontalizumab is a humanized IgG1 monoclonal antibody targets IFN-α. Rontalizumab can be used for the research of systemic lupus erythematosus[1].

HY-P991655

AGS-009	IFNAR HIV	Infection Inflammation/Immunology
AGS-009 is a humanized monoclonal neutralising antibody targeting *IFN-α*. AGS-009 significantly reduces activated lymphocytes, such as CD4 ⁺ and CD8 ⁺ T cells as well as B cells in SIV infection rhesus macaque models. AGS-009 can be used for autoimmune diseases like systemic lupus erythematosus (SLE) and HIV infections research .

HY-P991811

*Anti-Mouse IFN Alpha* Antibody (TIF-3C5)**	IFNAR	Inflammation/Immunology
Anti-Mouse IFN Alpha Antibody (TIF-3C5) reacts with the mouse IFNα. Anti-Mouse IFN Alpha Antibody (TIF-3C5) binds specifically to mouse IFNα species (IFN-α-A, IFN-α-1, IFN-α-4, IFN-α-5, IFN-α-11. and IFN-α-13) and does not bind murine murine IFNγ or IFNβ. Recommend Isotype Controls: Polyclonal Armenian hamster IgG, Isotype Control (HY-P990305) .

HY-P992348

DS-7011a	Toll-like Receptor (TLR)	Inflammation/Immunology
DS-7011a is a selective inhibitor targeting TLR7. DS-7011a inhibits IL-6 production induced by TLR7 stimulation and related responses in B cells and plasmacytoid dendritic cells. DS-7011a is internalized in a TLR7-dependent manner and accumulates in B cells, various dendritic cell subsets, and monocytes/macrophages. DS-7011a can be used in research related to systemic lupus erythematosus (SLE) .

HY-P992394

JNJ-55920839 CNTO-6358	IFNAR	Inflammation/Immunology
JNJ-55920839 (CNTO-6358) is a fully human immunoglobulin G1κ monoclonal antibody and a selective Interferon α/ω neutralizer, with a K_d value of 0.9-10.7 pM against hIFNα and a K_d of 1.44 pM against IFNω. JNJ-55920839 can be used in research related to systemic lupus erythematosus .

HY-P992059

Anti-Mouse CD1d Antibody (1B1)	CD1	Cancer
Anti-Mouse CD1d Antibody (1B1) is an antibody targeting mouse CD1d (K_d=12.5 nM). By inserting into the lipid-binding groove of CD1d, Anti-Mouse CD1d Antibody (1B1) overlaps with the binding sites of type I and type II NKT cell receptors (TCR), thereby effectively blocking TCR-mediated interactions. Anti-Mouse CD1d Antibody (1B1) activates antigen-presenting cells such as dendritic cells and macrophages, induces them to release IL-12p70, and increases the levels of key cytokines including IL-12, IFN-γ and *IFN-α* in mouse serum. Anti-Mouse CD1d Antibody (1B1) can be used in studies related to renal cancer, breast cancer and colon adenocarcinoma. When combined with anti-DR5 or anti-CD137 antibodies and chemotherapeutic drugs, Anti-Mouse CD1d Antibody (1B1) exhibits significant tumor inhibitory and even eradication effects in mice .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N8107

Matairesinol monoglucoside 2 Publications Verification	Structural Classification Monophenols other families Classification of Application Fields Lignans Other Diseases Phenols Phenylpropanoids Plants Disease Research Fields Source Classification	STING IFNAR HBV
Matairesinol monoglucoside is a STING activator. Matairesinol monoglucoside modulates the STING-TBK1-IRF3 signaling axis, promotes STING transcriptional expression, increases TBK1 and IRF3 phosphorylation. Matairesinol monoglucoside induces IFN-α and IFN-β production, reduces HBV DNA, HBsAg, and HBeAg expression. Matairesinol monoglucoside can be used for the research of hepatitis b virus (hbv) infection .

Cat. No.	Product Name	Chemical Structure

HY-126242S

Tyk2-IN-7

Tyk2-IN-7 is an orally active TYK2 JH2 inhibitor, binds to TYK2 JH2 domain with IC₅₀ and K_i.app of 0.00053 μM and 0.00007 μM, respectively. Tyk2-IN-7 provides a highly selective alternative to conventional TYK2 orthosteric inhibitors, inhibits TYK2/JAK1/JAK2 kinase domain. Tyk2-IN-7 can inhibit the IL-23 and IFN-α signaling pathways. Tyk2-IN-7 is commonly used in the study of inflammatory conditions such as colitis .

HY-13740S

Resiquimod-d5 1 Publications Verification
Resiquimod-d₅ is deuterium labeled Resiquimod. Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α .

HY-160144S2

(rac)-Lomedeucitinib
(rac)-Lomedeucitinib ((rac)-BMS-986322) is the racemate of Lomedeucitinib. Lomedeucitinib (BMS-986322) is a tyrosine protein kinase (TYK2) inhibitor. Lomedeucitinib has anti-inflammatory activity and significant inhibitory effect on IFNα (IC50=0.047 μM) production downstream of IL-12/TYK2. Lomedeucitinib is indicated for the study of plaque psoriasis and pruritus .

HY-163314S

Tyk2-IN-18-d3
Tyk2-IN-18-d3 (Compound 18) is a Tyk2 inhibitor with an IC₅₀ value of < 30 nM for both IL-23 and *IFNα*. Tyk2-IN-18-d3 can be used for research on autoimmune diseases .

Cat. No.	Product Name		Classification